Actuate Therapeutics Inc

NASDAQ:ACTU

Biotechnology

Healthcare
$2.09 +2.96%

+$0.06 today

Market cap
$50.01M
Beta
0.53
P/E (TTM)
-2.3
EPS (TTM)
-$0.92
52W Low $1.58High $9.22

Volume 0.03M

Average 0.16M

ACTU Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Actuate Therapeutics IncNASDAQ: ACTU

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income declines year over year

Q1 FY2026 net income of $5.63M (cash outflow) fell 10.9% year over year, ahead of the -14.9% change in trailing-twelve-month net income. Sequentially, it rose 23.5% from the prior quarter. Over 3 fiscal years it compounded at +3.3% a year.

Context

  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate of -$16.87M (-24.1%) for the fiscal year ending Dec 2026, a slowdown from the -18.5% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$5.63M+23.5% QoQ
Last fiscal yearDec 2025
-$22.23M-18.5% YoY
LTMMar 2026
-$21.54M-14.9% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-10.9%-21.6%-10.7 pp
1 year-18.5%-24.1%-5.6 pp
3-year CAGR+3.3%-4.1%-7.4 pp
5-year CAGR-31.9%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(22.23M) USD
Year-over-year change
+18.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ACTU compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -14.9% is the 6th highest of 9, against a peer median of -4.3%.
  • Over three fiscal years its annual growth of +3.3% compares with a peer median of +9.1%.
ACTU Competitors
Net Income for ACTU and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VORVor Biopharma Inc.LTM Mar 2026$883.08M USD+644.6%+96.2%—
ALECAlector, Inc.LTM Mar 2026$125.39M USD+1.6%+2.3%680.8%
NKTXNkarta, Inc.LTM Mar 2026$99.93M USD-10.2%-2.9%—
PEPGPepGen Inc.LTM Mar 2026$77.22M USD-24.4%+9.1%—
MOLNMolecular Partners AGLTM Mar 2026CHF 64.16M CHF+7.8%——
MCRBSeres Therapeutics, Inc.LTM Mar 2026$46.9M USD-164.3%—4088.8%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$40.19M USD-21.6%+11.9%—
ACTUActuate Therapeutics IncLTM Mar 2026$21.54M USD-14.9%+3.3%—
SPROSpero Therapeutics, Inc.LTM Mar 2026$15.24M USD+121.8%—27.8%
Peer median (excluding ACTU) —-4.3%+9.1%680.8%

Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(20.16M)(24.74M)(27.29M)(22.23M)
Depreciation & Amortization0000
Deferred Income Tax0000
Stock-Based Compensation654.07K423.54K2M6.05M
Change in Working Capital1.73M2.57M1.1M(3.05M)
Accounts Receivables0000
Inventory0000
Accounts Payables586.26K1.29M(1.5M)(512.54K)
Other Working Capital1.15M1.28M2.6M(2.53M)
Other Non-Cash Items(20.38K)123.46K2.35M20.25K
Operating Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)
Capital Expenditures0000
Acquisitions (Net)0000
Purchases of Investments0000
Sales of Investments0000
Other Investing Activities0000
Investing Cash Flow0000
Debt Repayment005.5M0
Common Stock Issued0023.96M24.03M
Common Stock Repurchased0000
Dividends Paid0000
Other Financing Activities00(1.93M)(302.83K)
Financing Cash Flow19.26M4.13M27.53M23.72M
Effect of Forex Changes0000
Net Change in Cash1.46M(17.49M)5.68M4.52M
Free Cash Flow(17.79M)(21.63M)(21.84M)(19.21M)

Actuate Therapeutics Inc

NASDAQ:ACTU

Intrinsic Alpha fair value

Locked

Current Price

$2.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.